Sapropterin's Role in Coenzyme Formation
Sapropterin (also known as tetrahydrobiopterin or BH4) is the active coenzyme form of biopterin, essential for synthesizing neurotransmitters and nitric oxide. It functions directly as the coenzyme (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin in enzymatic reactions, rather than being formed by a coenzyme process—its own formation occurs via the de novo biopterin synthesis pathway from GTP.
How Sapropterin Forms from GTP
Sapropterin arises through a multi-step pathway starting with GTP:
- GTP cyclohydrolase I converts GTP to dihydroneopterin triphosphate.[1]
- 6-Pyruvoyl-tetrahydropterin synthase (PTPS) rearranges it to 6-pyruvoyltetrahydropterin.[1]
- Sepiapterin reductase (SR), along with carbonyl and aldose reductases, reduces it to BH4 (sapropterin).[1][2]
This yields the (6R)-BH4 stereoisomer, the biologically active coenzyme. Disruptions here cause BH4 deficiency, treated with synthetic sapropterin (Kuvan).
How Sapropterin Functions as a Coenzyme
As (6R)-BH4, sapropterin acts as a cofactor in hydroxylation reactions by donating electrons and accepting/releasing protons:
- Phenylalanine hydroxylase (PAH): Converts phenylalanine to tyrosine (precursor to dopamine, norepinephrine). BH4 oxidizes to quinonoid-dihydrobiopterin (qBH2).[1][3]
- Tyrosine hydroxylase (TH): Tyrosine to L-DOPA (dopamine precursor).[1]
- Tryptophan hydroxylase (TPH): Tryptophan to 5-hydroxytryptophan (serotonin precursor).[1]
- Nitric oxide synthase (NOS): L-arginine to nitric oxide.[1]
Post-reaction, BH4 regenerates via dihydropteridine reductase (DHPR) using NADH: qBH2 → BH2 → BH4.[2][3]
<br />
Reaction cycle:<br />
Enzyme + substrate + BH4 → hydroxylated product + qBH2<br />
qBH2 + NADH → BH4 (via DHPR)<br />
Why Sapropterin in Therapy
Synthetic sapropterin treats PAH deficiency (PKU) by bypassing synthesis defects, restoring coenzyme levels to normalize phenylalanine metabolism.[3] It also aids BH4-responsive PKU variants where residual PAH activity amplifies with extra cofactor.
Risks and Limitations
Excess sapropterin can inhibit NOS or cause hypertension; it's ineffective in complete synthesis defects (e.g., GTPCH or DHPR deficiencies).[2] Patients monitor phenylalanine levels, as response varies (20-60% in PKU).[3]
[1]: National Institutes of Health - Genetics Home Reference: Tetrahydrobiopterin Deficiency
[2]: PubMed - Biopterin Metabolism
[3]: FDA Label: Kuvan (sapropterin)